NCT02747303
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients with leptomeningeal disease or metastases in the brain stem, midbrain, pons, medulla, or within 7 mm of the optic apparatus
https://ClinicalTrials.gov/show/NCT02747303